To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Novartis' Certican™ patent upheld by European Patent Office
Investigational transplant drug Certican is 'inventive' and patentable
26-02-2001: Novartis announced today that the Opposition Board at the European Patent Office in Munich has upheld the company's European patent for its investigational transplant
drug Certican™, which had been opposed by American Home Products (AHP). Certican, which is currently in Phase 3 clinical trials for the inhibition of transplant rejection, was held by the Board to
be 'inventive'. This confirmation of the drug's patentability endorses Novartis' program to continue its clinical development.
This is the latest chapter in the European patent dispute with AHP, who allege that Certican infringes patent rights it has licensed.
Novartis is pleased with the latest, very significant development, which underlines non-infringement decisions in Novartis' favour taken recently by the UK Court of Appeal and the District Court in the Hague.
Certican, (also known as 'RAD' or the non-proprietary name 'everolimus') is a novel immunosuppressive molecule, independently invented, patented and developed by Novartis as part of its longstanding commitment towards improving the outcome of transplantation and the quality of life in transplant patients. Novartis is committed to continuing the Certican global development program and to providing a product for worldwide clinical use at the earliest possible time.
This is where you can add this news to your personal favourites
- 1Drew Industrial Division of Ashland Specialty Chemical Company purchases industrial water-treatment business of London-based Fer
- 2Allegra® Launched in Japan
- 3LG-DOW Polycarbonate Plant Starts Production in Korea to Effectively Meet Regional Needs
- 4Caflon® surfactants from Univar as substitutes for banned nonylphenol ethoxylates
- 5Honeywell Appoints Terrence Hahn as Vice President and General Manager for Fluorine Products
- 6Knoll AG: Pharma business sold for $6.9 billion:
- 7Plurafac LF 303 - Plurafac LF 305: The new generation of low-foam surfactants
- 8Not just cars, but living organisms need antifreeze to survive
- 9Putting electronic cigarettes to the test
- 10Baytron P®– Gateway to a new generation of polymers